Founded in 1969, the company has achieved significant milestones through an immaculate performance history, always upholding the highest ethical and operational standards, with compliance to regulatory affairs.

Strongly dedicated to strategic planning and its vision, Pharmathen soon emerged as one of the largest independent generic development companies in Europe. With a pipeline of approximately ten generic molecules a year and vigorous export activities in over 80 countries, the company has reached export sales dynamics that amount to 70% of the group’s total annual sales.

Pharmathen’s core business is the development of complex generic products, advanced pharmaceutical technologies and platforms, out licensing of their marketing rights to multinationals and local pharmaceutical brands. As of September 2017, the company’s total headcount reached 1061 highly qualified professionals, all dedicated to the company’s vision, as a strong emerging player in the global pharmaceutical market.

With 3 state of the art research laboratories in Greece and India, the company is committed to scientific excellence and continuous R&D investments, aiming to enhance its product portfolio, provide innovative solutions and services to customers and patients, whilst maintaining and securing a strong financial performance.

Video Presentation :